Imagine trying to find the right key for a lock, but the lock changes shape every day. That is what treating brain tumors is like. This project builds a smart digital map that combines MRI scans with cellular data to pick the exact immunotherapy that fits a specific patient's tumor. It is like a matchmaking service for cancer drugs and patients.
Current brain cancer treatments fail because tumors are too diverse for a one-size-fits-all approach. Doctors lack the biomarkers to know which patients will actually respond to immunotherapy, leading to wasted resources and poor patient outcomes.
A Radio-multiomics hub and a data-driven selection algorithm that matches patients to immunotherapies by integrating MRI images with single-cell tissue maps.
If you are a drug developer dealing with inconsistent clinical trial results — this project developed a data-driven selection algorithm that matches patients to the most suitable immunotherapy. This reduces the risk of trial failure by identifying the right patient subsets from the start.
If you are a software provider dealing with the lack of biological context in radiology — this project developed a Radio-multiomics hub that integrates MRI images with tissue maps. This allows for more accurate monitoring of treatment efficacy and tumor progression.
If you are a diagnostic lab dealing with the high heterogeneity of glioblastomas — this project developed a patient stratification tool using single-cell multiomics. This enables the delivery of personalized therapy matching based on actual tumor-host interactions.
Based on available project data, no pricing or cost information is provided as the project is currently in the research and development phase.
Yes, the project establishes a framework for personalized therapy that is applicable to other cancers beyond glioblastoma and paediatric high-grade gliomas.
Based on available project data, the project adopts open science principles and FAIR data standards, though specific commercial licensing terms are not listed.
The tool is designed as a hub available to clinical professionals to perform patient stratification and interpret longitudinal follow-up through non-invasive MRI images.
The project period runs from 2024-01-01 to 2028-12-31, suggesting the tool will be refined through this window.
The consortium is well-balanced for a translation project, consisting of 15 partners across 10 countries. It features a strong academic base (7 universities and 4 research institutes) to handle the complex multiomics, while maintaining a 20% industry ratio with 3 companies (including 3 SMEs) to ensure the resulting AI tools are commercially viable and clinically applicable.
Contact the Katholieke Universiteit Leuven research office regarding the Radio-multiomics hub.
Contact us to identify potential licensing opportunities for the GLIOMATCH selection algorithm.
